Evaluation by Oncologists of Strategies for the Prevention and Treatment of Chemotherapy-induced Peripheral Neuropathies

Study Overview
=================
Brief Summary
-----------------
Chemotherapy induced peripheral neuropathy (CIPN) is one of the most deleterious adverse effect of neurotoxic anticancer drugs affecting up to 40% of patients. These neurotoxic anticancer agents include mainly: cisplatin (bronchopulmonary cancers), oxaliplatin (colorectal cancers), paclitaxel (breast cancers and bronchopulmonary cancers), docetaxel (breast cancers and bronchopulmonary cancers) and bortezomib (multiple myeloma). CIPN affects not only the quality of life of patients, it also has a major impact on oncology strategy, forcing oncologists to reduce dose-intensity, to stop an ongoing chemotherapy regimen and to change therapeutic strategies, with a risk of compromising patients' survival. There is no real preventive or curative treatment (except duloxetine) for CIPN and it is not known what is the practice of oncologists in France? However, it is essential to know the degree of sensitivity of oncologists to this problem and their practice. With this study, the investigators propose to assess the current practices of management by oncologists in France in 2019, for any type of practitioners of university hospital, or general hospital, for all type of neurotoxic anticancer drugs.

Detailed Description
-----------------
This observational and cross-sectional study will be conducted as a survey using the REDCap software and the response to this survey will be done online, in real time, with an automatic, secure and centralized data collection (CHU Clermont-Ferrand). French oncologist will be contacted by email thanks to the regional cancer networks. Answer to the survey will be done online.

Official Title
-----------------
Evaluation by Oncologists of Strategies for the Prevention and Treatment of Chemotherapy-induced Peripheral Neuropathies: Observational and Cross-sectional Study

Conditions
-----------------
Chemotherapy-induced Peripheral Neuropathy

Intervention / Treatment
-----------------
* Other: survey


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Oncologist Exclusion Criteria: pain physician

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Oncologists<br>French oncologists | Other: survey<br>* to assess the current practices of management by oncologists in France in 2019, for any type of practitioners of university hospital, or general hospital, for all type of neurotoxic anticancer drugs.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Treatment strategy for CIPN | Name of the drug used to treat CIPN and therapeutic adjustments, relay to a pain doctor and use of drugs) | at day 1 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Perception of effectiveness of the treatments used | Visual analogic scale: 0 no efficacy - 100 maximal efficacy | at day 1 | 
| Perception of safety of the treatments used to treat CIPN | Visual analogic scale: 0 unacceptable adverse effect - 100 acceptable adverse effects | at day 1 | 
| Treatment strategy for CIPN prevention | Name of the drug used to prevent CIPN and therapeutic adjustments | at day 1 | 
| Estimation by the oncologist of the percentage of patients affected by CIPN | Visual analogic scale: 0% - 100% of patients | at day 1 | 
| Proportion of assessments of the CIPN severity performed by the oncologist using a specific questionnaire | yes / no (percentage) if yes name of the questionnaire | at day 1 | 
| Proportion of CIPN assessments performed by the oncologist with a clinical examination | yes / no (percentage) | at day 1 | 
| Proportion of CIPN assessments performed by a neurological examination (neurologist) | yes / no (percentage) | at day 1 | 
| Age of oncologists | years | at day 1 | 
| Sex of oncologists | Male / female | at day 1 | 
| Organ or system speciality of oncologists | name of speciality | at day 1 | 
| Number of chemotherapy prescriptions | Number of chemotherapy | at day 1 | 
| Types of neurotoxic anticancer drugs prescribed | Name of drugs | at day 1 | 
| Working place | French region of practice and type of structure (public / private) | at day 1 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Peripheral Nervous System Diseases, Oncologists